Strain Selection for Generation of O-Antigen-Based Glycoconjugate Vaccines against Invasive Nontyphoidal Salmonella Disease

Luisa Lanzilao1☯, Giuseppe Stefanetti1☯, Allan Saul1, Calman A. MacLennan2,3, Francesca Micoli1, Simona Rondini1*

1 Sclavo Behring Vaccines Institute for Global Health S.r.l., a GSK company (formerly Novartis Vaccines Institute for Global Health S.r.l), Via Fiorentina 1, 53100, Siena, Italy, 2 Jenner Institute, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, United Kingdom, 3 Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, United Kingdom

☯ These authors contributed equally to this work.
* simona.x.rondini@gsk.com

Abstract

Nontyphoidal Salmonella, principally S. Typhimurium and S. Enteritidis, are a major cause of invasive bloodstream infections in sub-Saharan Africa with no vaccine currently available. Conjugation of lipopolysaccharide O-antigen to a carrier protein constitutes a promising vaccination strategy. Here we describe a rational process to select the most appropriate isolates of Salmonella as source of O-antigen for developing a bivalent glycoconjugate vaccine. We screened a library of 30 S. Typhimurium and 21 S. Enteritidis in order to identify the most suitable strains for large scale O-antigen production and generation of conjugate vaccines. Initial screening was based on growth characteristics, safety profile of the isolates, O-antigen production, and O-antigen characteristics in terms of molecular size, O-acetylation and glucosylation level and position, as determined by phenol sulfuric assay, NMR, HPLC-SEC and HPAEC-PAD. Three animal isolates for each serovar were identified and used to synthesize candidate glycoconjugate vaccines, using CRM197 as carrier protein. The immunogenicity of these conjugates and the functional activity of the induced antibodies was investigated by ELISA, serum bactericidal assay and flow cytometry. S. Typhimurium O-antigen showed high structural diversity, including O-acetylation of rhamnose in a Malawian invasive strain generating a specific immunodominant epitope. S. Typhimurium conjugates provoked an anti-O-antigen response primarily against the O:5 determinant. O-antigen from S. Enteritidis was structurally more homogeneous than from S. Typhimurium, and no idiosyncratic antibody responses were detected for the S. Enteritidis conjugates. Of the three initially selected isolates, two S. Typhimurium (1418 and 2189) and two S. Enteritidis (502 and 618) strains generated glycoconjugates able to induce high specific antibody levels with high breadth of serovar-specific strain coverage, and were selected for use in vaccine production. The strain selection approach described is potentially applicable to the development of glycoconjugate vaccines against other bacterial pathogens.
Introduction

Bacteria of the species *Salmonella enterica* causing human disease are divided into human-restricted typhoidal serovars (Typhi and Paratyphi) causing enteric fever, and nontyphoidal *Salmonella* (NTS) serovars, which have a broader host-range and are frequently zoonotic. Among the NTS serovars isolated worldwide from humans, *Salmonella* Enteritidis and Typhimurium rank as the most common (43.5%) and second most common (17.1%), respectively [1]. In developed countries NTS cause a mild self-limiting gastroenteritis with less than 2% mortality. In those countries, invasive nontyphoidal *Salmonella* (iNTS) disease is uncommon [2], with an estimated overall crude annual incidence of 49/100,000 population [3]. In contrast, in sub-Saharan Africa, *S. Typhimurium* and Enteritidis are the predominant cause of invasive bloodstream infections, especially amongst young children and HIV-infected individuals [4, 5]. The case-fatality rate of iNTS disease is up to 25% and the effectiveness of antibiotic treatment has been hampered by increasing multidrug resistance [4, 5].

Currently, there are no licensed vaccines against iNTS disease and efforts are ongoing to identify protective antigens and best strategies for vaccine development [4, 6, 7]. Lipopolysaccharide (LPS) has been implicated as a target of the protective immune response [8–11] and the serovar-specific O-antigen (OAg) of LPS have been employed in subunit vaccines, particularly glycoconjugate vaccines. OAg have been shown to elicit protective immunity against lethal challenge, with anti-OAg antibodies protective in adoptive transfer experiments [12–16]. It is known that OAg expression is regulated by several factors including serum exposure [17], growth phase [18], presence of micronutrients [17, 19, 20]. OAg length and density can determine bacterial pathogenicity [18, 21–23]. Bacterial LPS can demonstrate high levels of heterogeneity: OAg can vary in chain length and can have other modifications, such as glucosylation and O-acetylation of sugar residues in the repeating units [24–27]. Little is known about the influence of these OAg modifications on pathogenicity [27], and how OAg can vary among strains belonging to the same *S. Typhimurium* and *Enteritidis* serovar. As the variety of LPS modifications occurring in nature is not known, it is unclear whether these differences are critical for the development of an OAg-based vaccine, and what importance should be attached to selecting the OAg source.

Previous work [11] has shown that the highest anti-OAg antibody responses elicited by *S. Typhimurium* OAg-CRM197 conjugates are obtained from OAg with the highest glucosylation levels, OAg populations of medium (approximately 25 repeating OAg units) or mixed molecular weights (composed of both medium and high molecular weights: around 70 OAg repeating units) with an optimal OAg/CRM197 ratio of 1.5. Additionally, the interplay between glucosylation and O-acetylation appears to be important in eliciting bactericidal anti-OAg antibodies. Based on these findings, we screened a library of 30 *S. Typhimurium* and 21 *Enteritidis*, with the specific aim of identifying those most suitable for large scale OAg production and generation of OAg-conjugate vaccines cross-protective against endemic invasive African strains. The criteria used to down-select these strains were based on OAg production levels, safety (antibiotic susceptibility and known invasiveness) and recognition of antibodies generated against an endemic invasive African isolate. At the conclusion of this selection process, we were able to identify three strains for each serovar, all amenable to large-scale manufacture, and, in the case of *S. Typhimurium*, having different OAg features in terms of molecular size, O-acetylation and glucosylation level and position. We used the OAg from these strains to generate conjugate vaccines and evaluated the impact of OAg structure on immunogenicity. Our findings can help guide the selection of the most suitable OAg-producing strains for effective vaccines against iNTS disease.
Results
Strains Screening and Selection

The first criterion for NTS strain selection was based on the evaluation of their growth characteristics. All 51 NTS isolates (30 S. Typhimurium and 21 S. Enteritidis), were inoculated in Chemically Defined (CD) medium and grown overnight. We chose CD medium as a suitable growth medium for large-scale production [28]. Twenty-seven S. Typhimurium and 19 S. Enteritidis grew well reaching Optical Densities (ODs) of 3–6; 3 S. Typhimurium did not grow unless the medium was supplemented with casamino acids, while 2 S. Enteritidis grew poorly in CD medium reaching ODs of 1–1.5 (Tables 1 and 2). From this initial screening, only the isolates that grew to OD>3 in CD medium (27 S. Typhimurium and 19 S. Enteritidis) were selected for further analysis.

S. Typhimurium isolates. The second selection criterion was based on the production of OAg. OAg extracted from the selected strains were quantified and the isolates were categorized as low (< 400 μg/ml), medium (400–850 μg/ml) and high producing (≥ 850 μg/ml) strains (Table 1).

Nine strains were selected as high producers, but since we wanted to select strains with the highest safety profiles, one isolate was excluded because of resistance to aztreonam (1419), and another because of its human origin (2196). The OAg from the remaining 7 strains (1417, 1418, 1421, 2189, 2192, 2193, and 2198) were analyzed by Size Exclusion-High Pressure Liquid Chromatography (HPLC-SEC), Nuclear Magnetic Resonance (NMR) and flow cytometry.

OAg profiles showed peaks at high (HMW) or medium (MMW) molecular weight, in the range 63.8–87 kDa and 34.5–28.3 kDa, respectively [29, 30]. One isolate presented only MMW OAg (2192), while five presented both HMW and MMW populations (1417, 1418, 1421, 2189 and 2198) and one isolate (2193) showed only peaks at very low molecular weight (LMW), with very few/no repeating sugar units in the OAg chain (Table 1). Proton High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance (HR–MAS NMR) was performed directly on the bacteria and allowed detection of the typical OAg signals and identification of O-acetylation levels and positions. As well as D23580, one other isolate (1421) was O-acetylated on both rhamnose (Rha) and abequose (Abe), while the remaining isolates were O-acetylated on Abe only (Table 1, Fig 1).

FACS analysis performed with serum from mice immunized with a conjugate generated using OAg from the endemic D23580 strain [11] showed antibody binding to all 7 S. Typhimurium, confirming antigenic similarity between OAg from the invasive African human isolate and the selected animal strains (Fig 2A).

Further selection criteria were applied in order to identify among these 7 strains those most representative of the spectrum of S. Typhimurium in terms of OAg structural characteristics. Among the strains with OAg populations at two different average MW and O-acetylation on Abe only (2198, 2189, 1418, 1417), 2189 and 1418 were chosen on the basis of higher OAg production (Table 1). Among the strains presenting one OAg population (2192 and 2193) and O-acetylation only on Abe, 2192 was selected because 2193 produced mainly core sugars and previous work has shown a lack of immunogenicity for such OAg [16, 31]. Finally, strain 1421 was selected as the only representative strain presenting two OAg populations and O-acetylation on both Rha and Abe, similar to the D23580 African isolate.

S. Enteritidis isolates. The 19 strains selected based on growth characteristics in CD medium, were evaluated for OAg production. One strain was a low producer (< 400 μg/ml). There were 13 medium (400–850 μg/ml) and five high producers (≥ 850 μg/ml). In contrast to the S. Typhimurium OAg, less variability in MW distribution was found by HPLC-SEC.
Table 1. S. Typhimurium isolates.

| Isolate N. | Original collection/identification | Source | Country | Growth | OAg production (μg/mL) | OAg-producer | Antibiotic resistance | avMW OAg (KDa)* | O-acetylation | Fluorescent signal** |
|------------|-----------------------------------|--------|---------|--------|------------------------|--------------|----------------------|-----------------|--------------|-------------------|}
| 1415       | SGSC, LT5                         | Calf   | Zurich, Switzerland | CD medium | 436 | Medium | S | - | - | - |
| 1416       | SGSC, LT6                         | Pigeon | Visby, Sweden | CD medium | 735 | Medium | S | - | - | - |
| 1417       | SGSC, LT7                         | Lamb   | Fort Collins, USA | CD medium | 1300 | High | S | 68.7 and 28.3 | Abequose | 2322 |
| 1418       | SGSC, LT8                         | Mouse  | Denmark | CD medium | 1560 | High | S | 87 and 30.4 | Abequose | 2202 |
| 1419       | SGSC, LT9                         | Turkey | Minnesota, USA | CD medium | 1189 | High | Aztreonam | - | - | - |
| 1421       | SGSC, LT11                        | Rat    | Sweden | CD medium | 915 | High | S | 63.8 and 28.3 | Abequose, Rhamnose | 2442 |
| 1429       | SGSC, LT19                        | Human  | Surahammar, Sweden | CD medium | 696 | Medium | S | - | - | - |
| 1430       | SGSC, LT20                        | Hen    | Chile   | CD medium | 800 | - | S | - | - | - |
| 2181       | SGSC, SARA 1                      | Human  | Mexico | CD medium | 461 | Medium | S | - | - | - |
| 2183       | SGSC, SARA 3                      | Horse  | Rhode Island | CD medium | 22 | Low | Aztreonam, chloramphenicol | - | - | - |
| 2184       | SGSC, SARA 4                      | Rabbit | Indiana | CD medium | 106 | Low | Ampicillin | - | - | - |
| 2185       | SGSC, SARA 5                      | Rabbit | Mongolia | CD medium | 684 | Medium | S | - | - | - |
| 2186       | SGSC, SARA 6                      | Human  | Ohio   | CD medium | 133 | Low | S | - | - | - |
| 2187       | SGSC, SARA 7                      | Human  | Norway | Supplements | 1098 | - | S | - | - | - |
| 2188       | SGSC, SARA 8                      | Human  | Finland | CD medium | 561 | Medium | S | - | - | - |
| 2189       | SGSC, SARA 9                      | Parrot | California | CD medium | 990 | High | S | 80.8 and 31.6 | Abequose | 268 |
| 2190       | SGSC, SARA 10                     | Opossum | California | CD medium | 47 | Low | S | - | - | - |
| 2191       | SGSC, SARA 11                     | Opossum | Thailand | CD medium | 790 | Medium | S | - | - | - |
| 2192       | SGSC, SARA 12                     | Horse  | Louisiana | CD medium | 1172 | High | S | 34.5 | Abequose | 959 |
| 2193       | SGSC, SARA 13                     | Horse  | France  | CD medium | 864 | High | S | < 5.5 | Abequose | 807 |

(Continued)
Table 1. (Continued)

| Isolate N. | Original collection/identification | Source | Country | Growth | OAg production (μg/mL) | OAg-producer | Antibiotic resistance | avMW OAg (kDa)* | O-acetylation | Fluorescent signal** |
|------------|----------------------------------|--------|---------|--------|------------------------|-------------|----------------------|-----------------|--------------|---------------------|
| 2194       | SGSC, SARA 14                    | Horse  | Panama  | Supplements | 784            | -            | S                    | -               | -            |                     |
| 2195       | SGSC, SARA 15                    | Dog    | Texas   | CD medium | 567            | Medium       | S                    | -               | -            |                     |
| 2196       | SGSC, SARA 16                    | Human  | North Carolina | CD medium | 1400          | High          | S                    | -               | -            |                     |
| 2197       | SGSC, SARA 17                    | Human  | Yugoslavia | CD medium | 508            | Medium       | S                    | -               | -            |                     |
| 2198       | SGSC, SARA 18                    | Horse  | Iowa    | CD medium | 393            | High          | S                    | 85.7 and 30.4 | Abequose     | 2927                |
| 2199       | SGSC, SARA 19                    | Human  | Mexico  | Supplements | 924            | -            | S                    | -               | -            |                     |
| 2200       | SGSC, SARA 20                    | Human  | France  | CD medium | 370            | Low          | S                    | -               | -            |                     |
| 2201       | SGSC, SARA 21                    | Heron  | Oregon  | CD medium | 312            | Low          | S                    | -               | -            |                     |
| SA5983     | Lab of Foodborne Zoonoses Health | Chicken | Canada    | CD medium | 556            | Medium       | S                    | -               | -            |                     |
| SA5984     | Lab of Foodborne Zoonoses Health | Pig    | Canada   | CD medium | 476            | Medium       | S                    | -               | -            |                     |
| D23580     | Malawi-Liverpool-Wellcome Trust Clinical Research Programme | Human, invasive isolate | Malawi | CD medium | 699            | Medium       | Chloramphenicol, ampicillin, kanamycin, streptomycin, sulphonamid, trimethoprim | 82.6 and 28.3 | Abequose, Rhamnose | -                   |
| LT2        | Novartis Master Culture Collection | Human, lab strain | UK   | CD medium | 1021          | High          | S                    | 82.6 and 28.3 | Abequose     | -                   |
| SL1344     | University of Birmingham         | Calf, laboratory strain | UK   | CD medium | 702            | High          | S                    | 82.6 and 28.3 | Abequose     | -                   |

SGSC: Salmonella Genetic Stock CentreSARA: Salmonella reference collection A. CD: Chemically DefinedS: sensitive to ampicillin, amoxicillin, aztreonam, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, chloramphenicol, cotrimoxazole, meropenem

*avMW: average molecular weight, as determined by HLP-SEC

**values represent the geometric mean of the fluorescent signal as determined by FACS

doi:10.1371/journal.pone.0139847.t001
All the strains produced a major species of similar average MMW of about 30 kDa (Table 2).

Because of the similarity of OAg MW, in addition to quantification by phenol sulfuric assay, S. Enteritidis sugar production was quantified by OAg peak areas, as measured by HPLC-SEC (dRI, differential Refractive Index). While phenol sulfuric assay estimates the total sugar content, including core sugars with few or no OAg repeating units, analysis by HPLC-SEC allows selection of peaks related to longer OAg, normally corresponding to MMW chains, which we targeted for conjugate production [11]. Quantification of longer OAg chains by HPLC-SEC correlated (p<0.05 by Spearman correlation) with total sugar content by phenol sulfuric assay (Fig 3).

From this comparison, 6 isolates (IV3456074, IV3453219, 502, 506, 618 and 710) were selected which showed high sugar production as quantified by both phenol sulfuric assay and HPLC-SEC. Therefore, for these isolates high sugar levels were mostly due to long OAg-chains rather than LMW populations. *Salmonella* FACS analysis, performed with serum containing anti-OAg antibodies raised to the endemic D24359 invasive isolate, confirmed good binding of

*Fig. 1. HR-MAS NMR showing O-acetylation patterns for S. *Typhimurium* D23580 and 2198 OAg and S. *Enteritidis* 506 OAg, as examples. O-acetylation sites for *S. Typhimurium* OAg have been determined [30]. Determination of sites for *S. Enteritidis* is ongoing.*

doi:10.1371/journal.pone.0139847.g001
| Isolate N. | Original collection/identification | Source | Country | Growth | OAg production (μg/mL) | OAg-producer | Antibiotic resistance | avMW OAg (KDa)* | O-acetylation | Fluorescent signal** |
|-----------|-----------------------------------|--------|---------|--------|------------------------|-------------|----------------------|-----------------|--------------|-------------------|
| IV3452001 | EASSA 3;M2008-10019928             | Chicken | Hungary | CD medium | 873 | High | S | 32.4 | - | - |
| IV3452067 | EASSA 3;M2008-10022324             | Chicken | Hungary | CD medium | 1005 | High | S | <5.5 | - | - |
| IV3453219 | EASSA 3;PL005174953749              | Cattle | Poland | CD medium | 845 | Medium | S | 82.6 and 30.5 | Present | 1169 |
| IV3456065 | EASSA 3;09CEB11144SAL               | Pig    | France  | CD medium | 443 | Medium | S | 80.0 (shoulder) and 34.4 | - | - |
| IV3456074 | EASSA 3;09CEB495SAL                | Chicken | France  | CD medium | 685 | Medium | S | 34.4 | Present | 1958 |
| 394       | SA, EASSA 2;E187                   | Chicken | France  | CD medium | 585 | Medium | - | 32.6 | - | - |
| 396       | SA, EASSA 2;151                   | Chicken | France  | CD medium | 862 | High | - | 32.6 | - | - |
| 502       | SA, EASSA 2;salm46962              | Chicken | Germany | CD medium | 740 | Medium | S | 77 and 30.5 | Present | 1373 |
| 505       | SA, EASSA 2;salm50830              | Chicken | Germany | CD medium | 562 | Medium | - | 32.6 | - | - |
| 506       | SA, EASSA 2;salm50157              | Chicken | Germany | CD medium | 841 | Medium | - | 32.6 | Present | 1118 |
| 507       | SA, EASSA 2;salm50337              | Chicken | Germany | CD medium | 722 | Medium | - | 32.6 | - | - |
| 596       | SA, EASSA 2;P3S245-247             | Chicken | Spain   | CD medium (poor) | 61 | Low | Ampicillin, amoxicillin | 28.7 | - | - |
| 599       | SA, EASSA 2;P3S329-331             | Chicken | Spain   | CD medium | 388 | Low | - | 28.7 | - | - |
| 606       | SA, EASSA 2;P3S395-397             | Chicken | Spain   | CD medium | 792 | Medium | - | 172.8 (shoulder) and 30.5 | - | - |
| 609       | SA, EASSA 2;P3S434-436             | Chicken | Spain   | CD medium | 409 | Medium | - | 29.6 | - | - |
| 618       | SA, EASSA 2;P3S545-547             | Chicken | Spain   | CD medium | 885 | High | S | 29.6 | Present | 1102 |
| 710       | SA, EASSA 2;A4S13981400K3          | Chicken | Spain   | CD medium | 832 | Medium | S | 32.6 | Present | 1095 |
| 720       | SA, EASSA 2;A4S514516S3            | Chicken | Spain   | CD medium | 714 | Medium | - | 32.6 | - | - |
| 732       | SA, EASSA 2;A4S964966S3            | Chicken | Spain   | CD medium | 879 | High | Ampicillin | 85.7 (shoulder) and 36.5 | - | - |
| 910       | SA, EASSA 2; 16ex                  | Bovine  | France  | CD medium (poor) | 205 | Low | - | 32.6 | - | - |
| 963       | SA, EASSA 2;4458 ex                | Chicken | France  | CD medium | 577 | Medium | - | 74.8 (shoulder) and 32.6 | - | - |
| D24359    | Malawi-Liverpool-Wellcome Trust Clinical Research Programme | Human, invasive isolate | Malawi | CD medium | 1097 | High | S | 32.6 | - | - |

EASSA: European Antimicrobial Susceptibility Surveillance in Animals
CD: Chemically Defined
S: sensitive to ampicillin, amoxicillin, aztreonam, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, chloramphenicol, cotrimoxazole, meropenem
*avMW: average molecular weight, as determined by HLP-SEC
**values represent the geometric mean of the fluorescent signal as determined by FACS

doi:10.1371/journal.pone.0139847.t002
Fig 2. FACS analysis of selected 
S. Typhimurium (A) and 
S. Enteritidis strains (B). Bacteria were 
incubated with pooled sera of mice immunized with conjugates synthesized using OAg from invasive human 
strain S. Typhimurium D23580 (A) and 
S. Enteritidis D24359 (B).

doi:10.1371/journal.pone.0139847.g002
these antibodies to all isolates (IV3453219, IV3456074, 502, 506, 618, 710) (Fig 2B). S. Enteritidis isolates showed less variability than S. Typhimurium in terms of O-acetylation, and all were characterized by having low levels (≤ 30%) of O-acetyl groups (Fig 1).

**Fermentation and OAg Purification**

**S. Typhimurium isolates.** The four selected S. Typhimurium strains were fermented in CD medium and high cell densities (OD > 35) were reached in less than 15 h (duplication time ranged from 1.2 to 1.6 h) for all, except strain 1421 (S1A Fig), which reached a plateau at OD 7 with no further growth. On the basis of these fermentation findings, 1421 was down-selected and OAg was purified from 2189, 1418 and 2192 strains.

Two liters of fermentation broth were subjected to acid hydrolysis and OAg were further purified from 0.8–1.9 L hydrolyzed broth [29]. The purification process gave good overall yields (always above 70%) and 15.7–18.4 mg/OD of pure OAg were obtained per L of fermentation broth, according to the specific strain. Considering that fermentations were stopped at ODs ranging from 34 to 57, 0.5 to 1.0 g of OAg were recovered per L of fermentation broth.

**S. Enteritidis isolates.** The 6 selected S. Enteritidis strains were fermented in CD medium, but fermentation was not successful for strains IV3456074, 506 and 710 which reached ODs of 7–10 only (reasons and possible improvements in fermentation were not investigated). In contrast, strains IV3453219, 502 and 618 grew to satisfactory cell densities (S1B Fig). 618 required a more complex medium, but this was still compatible with large-scale production (medium ingredients not derived from animal sources). As for S. Typhimurium isolates, OAg purification recoveries for S. Enteritidis were > 65% and 12.7–24.2 mg/OD of pure OAg were obtained per L of fermentation broth.

**OAg Characterization**

All purified OAg were characterized by good purity, with protein and nucleic acid content <1% (weight to weight with respect to sugar content) and endotoxin level < 0.1 EU/μg of
sugar. High-Performance Anion-Exchange pulsed amperometric detection (HPAEC-PAD) and $^1$H NMR analysis confirmed the presence of the expected sugars constituting the OAg chain, with rhamnose, mannose, galactose and abequose ($S$. Typhimurium) or tyvelose ($S$. Enteritidis) in 1:1 molar ratios. All $S$. Enteritidis OAg showed low glucosylation levels (from 9 to 15%), while more variability was found for $S$. Typhimurium OAg (from 24 to 84%). As determined by HR-MAS NMR performed directly on bacteria, O-acetylation levels on purified OAg were low for all $S$. Enteritidis strains and variable for $S$. Typhimurium (Table 3).

Because of their high variability, OAg from $S$. Typhimurium isolates have been characterized in further detail by Micoli et al. [30].

OAg Conjugation to CRM$_{197}$

Acid hydrolysis was performed on the bacteria to extract OAg (plus core sugars) by removing lipid A. This process cleaves the labile linkage between the lipid A and the KDO sugar at the end of the core region. This sugar, quantified by semicarbazide/HPLC-SEC method [29] was in a ratio close to 1 with N-acetyl glucosamine (GlcNAc, a unique sugar of the core region, determined by HPAEC-PAD) for all the OAg, confirming that the delipidation process left one KDO sugar per OAg chain. The KDO was used for introducing ADH and then SIDEA linkers, and for binding the OAg to CRM$_{197}$ [11, 32, 33]. For all OAg, conjugation was efficient, with no residual unconjugated protein in the mixture. Purification by hydrophobic interaction chromatography allowed removal of unconjugated sugar chains.

The main characteristics of the conjugates obtained are reported in Table 3. For all of them, Kd values were higher than those of free OAg and free protein (Kd of CRM$_{197}$ of 0.72), confirming the larger size of the conjugate with respect to free components. All conjugates presented a similar saccharide to protein weight/weight ratio.

Immunogenicity Studies

$S$. Typhimurium conjugates. Groups of eight mice were immunized three times at two week intervals with six different $S$. Typhimurium conjugates synthesized using OAg from six different strains (Table 3): 2192, 1418, 2189 are the animal strains selected after the screening process, D23580 is the invasive human isolate, LT2 and SL1344 are common laboratory isolates that were included as additional comparators. All $S$. Typhimurium conjugates were immunogenic showing dose-dependency of the anti-OAg IgG response (Fig 4A). Anti-OAg IgG levels measured by Enzyme Linked Immunosorbent Assay (ELISA) (OAg purified from D23580 was

|                | Glc (%) | OAc (%) | Kd  | Kd unconjugated OAg | OAg/CRM$_{197}$ w/w ratio |
|----------------|---------|---------|-----|---------------------|----------------------------|
| $S$. Typhimurium 2192 | 24      | 100     | 0.49| 0.67                | 1.7                        |
| $S$. Typhimurium 1418 | 84      | 73      | 0.48| 0.56 and 0.67       | 1.7                        |
| $S$. Typhimurium 2189 | 51      | 58      | 0.46| 0.57 and 0.68       | 2.0                        |
| $S$. Typhimurium D23580 | 39     | 142     | 0.44| 0.58 and 0.68       | 2.1                        |
| $S$. Typhimurium LT2   | 11      | 64      | 0.47| 0.58 and 0.68       | 1.9                        |
| $S$. Typhimurium SL1344 | 8      | 75      | 0.43| 0.58 and 0.68       | 2.1                        |
| $S$. Enteritidis 502    | 12      | 22.4    | 0.50| 0.62 and 0.53       | 1.7                        |
| $S$. Enteritidis 618    | 15      | 10      | 0.55| 0.62                | 1.2                        |
| $S$. Enteritidis IV3453219 | 11  | 31.6    | 0.52| 0.65 and 0.52       | 1.8                        |
| $S$. Enteritidis D24359 | 9       | 35.4    | 0.52| 0.62                | 1.2                        |

doi:10.1371/journal.pone.0139847.t003
used as coating agent) were not significantly different for the group of S. Typhimurium conjugates when tested at 8 μg/dose.

At the 1 μg dose, the 2189 conjugate elicited significantly higher anti-OAg IgG than LT2- and SL1344-conjugates at day 42, (p = 0.04) (Fig 4A). When the same vaccine sera were tested by ELISA against all six OAg (purified and used as ELISA plate coating agents) (Fig 4B), a

---

Fig 4. Immunogenicity of S. Typhimurium OAg-conjugate vaccines. (A) Anti-OAg IgG at different time-points following immunization with various conjugates administered at 1 and 8 μg doses (D23580 OAg was used as coating agent); (B) Anti-OAg IgG response of the six conjugates using both homologous and heterologous OAg for plate coating (day 42, 8 μg/dose); (C) Serum bactericidal Activity (SBA) performed using pooled sera of mice belonging to the same immunization group against a total of 11 S. Typhimurium strains. Not all strains were tested against each conjugate-serum. Lab strains LT2, SL1344; Malawi endemic isolates: D23580, D25352, D22477, D24545, D24533; Kenya endemic isolates: Ke237, Ke238, Ke244, Ke249 (solid bars represent the geometric means; each dot represents a different S. Typhimurium isolates); (D) FACS analysis performed using pooled sera of mice belonging to the same immunization group of 14 S. Typhimurium strains (lab strains: LT2 and SL1344, animal isolates: 1418, 2189, 2192; Malawi endemic strains: D23580, D22477, D24533, D24545, D25352; Kenyan endemic strains: Ke237, Ke238, Ke244, Ke249) incubated with sera from mice immunized with all S. Typhimurium conjugates (solid bars represent the geometric means; each dot represents a different S. Typhimurium isolates).

doi:10.1371/journal.pone.0139847.g004
strain-specific response was clearly detected with the D23580-conjugate, which induced high anti-OAg IgG levels when measured against the homologous D23580 OAg, but lower anti-OAg IgG levels when measured against OAg from all other sources (significant differences, \( p < 0.05 \), found between anti-D23580 OAg and anti-1418, -2189 and -2192 OAg). No such strain specificity was found for the other sera (Fig 4B). Significantly higher anti-OAg IgG were detected in sera from 1418- and 2189-conjugates, compared with D23580- conjugate, when the ELISA plate coating was with LT2, SL1344 and 2189 OAg.

To further understand the specificities of the anti-OAg IgG raised to the vaccines, mouse sera were incubated with different *Salmonella* serovars/strains containing different OAg determinants, so that antibodies recognizing fine specificities present on each strain could be adsorbed out and a signal reduction, attributable to a lack of those antibodies, recorded (Table 4, Fig 5A).

Anti-OAg ELISA signal was reduced for all conjugate sera when pre-adsorbed with *S. Typhimurium* strains (D23580 and LT2), consistent with most anti-OAg IgG targeting O:4,5. Adsorption with the other serovars did not produce a substantial decrease in ELISA signal, suggesting that either relatively little anti-O:1 and O:12 IgG are generated, or they bind OAg poorly compared to anti-O:4,5 IgG. D23580-conjugate serum demonstrated strain-specificity once again, with strong ELISA signal reduction occurring only when the serum was incubated with homologous D23580 strain, but not with LT2. This suggests that anti-D23580 OAg IgG are mainly directed against a specific D23580 epitope not present on other *S. Typhimurium* OAg. We speculate that this epitope is formed by the additional O-acetylation groups detected on the Rha residue of the OAg repeating unit (Table 4, Fig 5A) [11, 30]. Finally, we searched for anti-OAg IgG directed against internal determinants, such as O:1,12, by coating the ELISA plates with OAg from different *Salmonella* serovars/strains and incubating conjugate sera either not adsorbed, or following specific adsorption (Table 4, Fig 5B). These experiments suggested that the majority of anti-OAg IgG elicited by all conjugates were against the O:5 determinant, as shown by testing sera pre-adsorbed with SL7488 (a strain expressing O:1,4,12, so that anti-O:1,4,12 IgG would be adsorbed out) against OAg from both *S. Typhimurium*
D23580 and LT2 (a situation in which remaining anti-O:5 IgG could be detected). Anti-O:4, anti-O:1 and anti-O:12 IgG were also detected, but at much lower levels than anti-O:5 IgG. The only exception was D23580-conjugate, which did not appear to elicit IgG with anti-OAg specificities other than to O:5 and Rha-acetylation. When evaluating ELISA signals to O:1,12 (coating with *S*. *Paratyphi* A or *S*. *Enteritidis*), the LT2 and 1418-conjugates elicited more specific antibodies than the other conjugates. Comparing this O:1,12 signal with O:12 only (coating with *S*. *Enteritidis* and pre-adsorption of sera with *S*. *Senftenberg*), there was a strong signal reduction with O:12 alone when testing serum raised to the 1418-conjugate, but not the LT2 conjugate. The finding suggests that more anti-O:1 than anti-O:12 IgG is induced by the 1418 vaccine, and the opposite for the LT2 vaccine. This is consistent with the known OAg structure of 1418 which is characterized by glucosylation of galactose at C6 [30], the basis of O:1 determinant.

Analysis of serum bactericidal activity (SBA) showed that antibodies induced by *S*. *Typhimurium* conjugates induced different levels of susceptibility/resistance to killing (Fig 4C). Of a
total of 11 strains tested (not all strains were tested against each conjugate, more details in S1 Table), 1 Malawi strain (D25352) was completely resistant to killing when tested with the three selected S. Typhimurium conjugate. The 2192 conjugate was unable to kill 4 of the 11 strains. By FACS analysis (Fig 4D, S2 Table), all sera from the S. Typhimurium conjugates were able to bind 13 out of 14 S. Typhimurium strains tested, with one Malawi isolate (D24533) bound only by sera from D23580 and 1418 conjugates.

**S. Enteritidis conjugates.** A parallel immunogenicity study, with three immunizations of 1 μg or 8 μg at two weeks intervals in groups of eight mice, was conducted to evaluate the four S. Enteritidis conjugates synthesized using OAg from 4 different strains (Table 3): 502, 618, IV3453219 were the animal strains selected from the screening process, while D24359 is the invasive human isolate included as comparator. Low anti-OAg IgG were induced with the 1 μg dose (Fig 6A), while higher IgG levels were present following immunization with the 8 μg dose, except with the IV3453219-conjugate.

There was large intergroup variation in the antibody responses to the S. Enteritidis conjugate vaccines, with more than one non-responding mouse in each group. No clear strain-specific response was detected, consistent with the lack of difference between the OAg extracted from all the S. Enteritidis source strains (Fig 6B, Table 3).

SBA suggested that S. Enteritidis strains (10 strains tested, also see S3 Table for details) are generally more resistant to antibody-dependent complement-mediated killing than S. Typhimurium strains. Geometric mean SBA titers were almost 2 log10 lower for S. Enteritidis compared with S. Typhimurium, and some isolates were fully resistant to killing. Nevertheless, all S. Enteritidis conjugate vaccines elicited sera with bactericidal activity against some S. Enteritidis isolates (Malawi strains D24359 and D24953 and two animal isolates 618 and 502 were completely resistant to complement-mediated killing) and no significant differences were detected between the killing abilities of the different sera (Fig 6C).

By FACS analysis, antibodies raised to all S. Enteritidis conjugates were able to bind all the 10 strains tested, with 618-conjugate sera giving the highest fluorescence values (Fig 6D, S4 Table).

**Discussion**

With the final aim of producing an OAg-based vaccine against S. Typhimurium and Enteritidis, we investigated a panel of NTS isolates to identify the most suitable OAg sources for OAg-CRM197 glycoconjugate vaccine development. An overview of the selection process we underwent is given in Table 5.

The majority of S. Typhimurium and S. Enteritidis strains in our collections were able to grow in defined medium and produced a wide range of OAg quantities. Fermentation of selected high OAg-producing NTS strains (non-invasive and antibiotic susceptible) was effective and yielded up to 24.2 mg/OD/L. This amount could translate into up to 40 g of purified OAg, obtained from one single 50 L fermentation run, considering a final OD 35 and an average purification process yield of 70%. By way of comparison, this corresponds to more than 4 times the amount of Vi antigen that is recovered from *Salmonella* Ty2 in a production process [34]. These evaluations are particularly important for vaccines needed in resource-poor settings, where developing country manufacturers may perform cGMP vaccine production and low costs and feasibility of manufacture are crucial elements.

Two of the three S. Typhimurium strains that were selected as OAg source (1418 and 2189), produced OAg of similar molecular weight, with two main populations of 28–31 and 80–87 kDa [30]. One isolate (2192) presented only one main peak of approximately 34.5 kDa [30]. Glucosylation levels ranged from 24% (2192) to 84% (1418), and O-acetylation levels (on Abe)
from 58% (2189) to 100% (2192) (Table 3). Although not part of the selection process, we also examined two laboratory isolates and the Malawian D23580 invasive isolate. Their OAg presented similar features to those of the animal isolates, except for the additional O-acetylation site on Rha found in the Malawian isolate [30] (Table 3). Contrary to what has been previously described [35, 36], the S. Enteritidis isolates tested were more homogeneous than the S.
Typhimurium isolates, with the majority of them producing only one OAg molecular weight population of 29.6–32.6 kDa with generally low glucosylation and low O-acetylation levels and the same O-acetylation position [37] (Table 3).

The conjugation process employed here does not modify the OAg repeating unit, maintaining native OAg structures, so that immunogenicity could be correlated with OAg structure and specific strain characteristics [33]. Therefore, by preparing conjugates with OAg representative of different structures, we aimed to evaluate the influence of OAg structure on immunogenicity. This was particularly relevant for the S. Typhimurium serovar, as it showed the highest OAg diversity. Data obtained with the S. Typhimurium conjugates indicated that the presence of Rha-O-acetylation in S. Typhimurium D23580 generates an immunodominant epitope with much of the induced anti-OAg antibodies directed against it [11]. The lack of binding, by ELISA (Fig 5B) and by FACS (data not shown), against S. Paratyphi OAg, which has also been found O-acetylated on C–2/C–3 Rha [38] (total OAc 68%), may hint for the presence of a structural epitope, specific for S. Typhimurium OAg chain. A similarly specific antibody response was not induced by the OAg used to generate the other vaccines. In contrast to the D23580-conjugate, all other OAg-conjugates lacking Rha-O-acetylation induced an antibody response against other OAg determinants, principally O:4 and O:5. When aiming to develop a vaccine with the broadest possible coverage, the strain-specific response identified with the D23580-conjugate is a potential issue, as analysis of OAg structures of endemic Kenyan isolates [37] has shown that invasive isolates may or may not have Rha-O-acetylation. Therefore, a S. Typhimurium OAg-based vaccine for Africa would need to induce antibodies capable of binding to both forms of OAg (with or without Rha-O-acetylation). From our findings, the OAg production strain should lack Rha-O-acetylation (as for all three selected Typhimurium strains).

Table 5. Workflow of strain selection process.

| Selection Criteria                                      | Outcome for S. Typhimurium                                      | Outcome for S. Enteritidis                                      |
|--------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------------|
| Growth in CD medium                                     | • 30 Typhimurium isolates screened                              | • 21 Enteritidis isolates screened                             |
|                                                        | • 27 selected                                                   | • 19 selected                                                  |
| OAg production level (>850 µg/ml)                       | • 9 selected for next step                                      | • 6 selected for next step                                     |
|                                                        | ○ 1417, 1418, 1421, 2189, 2192, 2193, 2198, 1419 and 2196        | ○ IV3456074, 506, 710, IV3453219, 502 and 618                   |
| Safety (exclusion of isolates with antibiotic resistance and human origin) | • 1419, 2196 excluded                                           | • No exclusion                                                 |
|                                                        | • 7 selected for next step                                      | • Same 6 selected for next step                                |
|                                                        | ○ 1417, 1418, 1421, 2189, 2192, 2193, and 2198                  |                                                                 |
| FACS analysis with serum from mice immunized against invasive Typhimurium/Enteritidis OAg | • No exclusion                                                  | • No exclusion                                                 |
|                                                        | • Same 7 selected for next step                                 | • Same 6 selected for next step                                |
| OAg populations and O-acetylation levels representative for the spectrum of OAg features | • 3 excluded                                                   | • No exclusion                                                 |
|                                                        | • 4 selected                                                   | • Same 6 selected for next step                                |
|                                                        | ○ 1418, 2189 (OAg populations at two MW, O-acetylation on Abe) |                                                                 |
|                                                        | ○ 2192 (OAg populations at 1 MW, O-acetylation on Abe)         |                                                                 |
|                                                        | ○ 1421 (OAg populations at 2 MW, O-acetylation on both Rha and Abe) |                                                                 |
| Fermentation                                           | • 1421 excluded                                                | • 3 excluded: IV3456074, 506 and 710                          |
|                                                        | • 3 selected for immunogenicity studies                        | • 3 selected for immunogenicity studies                        |
|                                                        | ○ 1418, 2189 and 2192                                         | ○ IV3453219, 502 and 618                                      |

CD: Chemically Defined

doi:10.1371/journal.pone.0139847.t005
Evaluating whether SBA could discriminate further among Typhimurium conjugates and most specifically between the three selected strains (which were tested against a panel of 11 strains), we found that the 2192-conjugate did not elicit bactericidal antibodies against 4 of 11 isolates. We do not understand the reason for this finding, but S. Typhimurium 2192 was the only isolate with a single OAg population and had the lowest glucosylation levels, factors which may both influence the generation of functional anti-OAg antibodies, as suggested in previous work [11]. Although not bactericidal, 2192-conjugate antibodies bound the tested S. Typhimurium isolates as for the other conjugates. Nevertheless, isolate D24533 was not bound by IgG elicited by the vaccine sera except for D23580- and 1418-conjugates (S3 Table). Surprisingly, the same isolate was killed in SBA (S1 Table), suggesting potential bactericidal activity of other Ig antibody classes (most likely IgM). Taken together, these data show that ELISA, SBA and FACS studies can provide different insights into the overall immunogenicity of candidate vaccines.

When we examined S. Enteritidis conjugates, we found that all produced lower serum titers and antibody-binding fluorescence signals by SBA and FACS. This is consistent with what we and others have previously observed [37, 39], that S. Enteritidis isolates are inherently more resistant than S. Typhimurium to antibody-mediated killing. We have previously hypothesized that differences in OAg expression levels [37] may partly explain this. Although we have been able to correlate OAg levels with serum resistance for Kenyan S. Typhimurium isolates, we were unable to find such correlation for S. Enteritidis isolates, indicating that other factors are relevant for this inherent resistance [37].

Consistent with the OAg homogeneity found among S. Enteritidis isolates, no isolate-specific antibody responses were identified following immunization with the S. Enteritidis conjugates. However, the IV3453219-conjugate generated the lowest anti-OAg IgG levels, and the 618-conjugate generated the highest SBA titers and FACS signal. The reasons for such differences remain unknown, and we speculate that additional factors, beyond what we assessed here, may contribute to differences in magnitude and functionality of the antibody responses elicited by these S. Enteritidis conjugates.

In summary, we undertook an extensive strain selection process to identify S. Typhimurium and S. Enteritidis isolates that could be used as safe and effective source for efficacious vaccines against NTS disease in Africa. We were able to identify three animal isolates for each serovar with characteristics suitable for large-scale OAg manufacture. The immunogenicity of the corresponding conjugate vaccines was used as a final step for OAg strain selection. Although we were not able to fully explain our findings, we concluded that S. Typhimurium strains 1418 and 2189, whose conjugates showed the broadest SBA activity could be selected as promising strains for a S. Typhimurium vaccine, while S. Enteritidis strains 502 and 618, whose conjugates had the highest immunogenicity, could be selected for a S. Enteritidis conjugate vaccine. Considering the ability of adjuvants to influence immunogenicity and breadth of antibody responses, their use is currently being explored for both S. Typhimurium and Enteritidis OAg conjugates. A similar approach could be used to determine which strains to use for the development of glycoconjugate vaccine against other bacterial pathogens.

Materials and Methods

Origin and Growth of Bacterial Strains

We received 30 S. Typhimurium strains from University of Calgary, Canada (Salmonella Genetic Stock Centre, SGSC): 20 of them belonged to the Salmonella reference collection A (SARA) [40]; 8 belonged to the LT2-collection [41]; 2 were from the lab of Foodborne Zoonoses, Health Canada in 2001 (Table 1). We also obtained 21 S. Enteritidis strains from Quotient Bioresearch Limited, UK, which were isolated by the European Antimicrobial Susceptibility
Surveillance in Animals (EASSA), coordinated by the European Animal Health Study Centre, Brussels (CEESA). Those strains belonged to CEESA EASSA collections II and III [42] (Table 2). The clinical S. Typhimurium (D22477, D24533, D24545, D25352, D23580) and S. Enteritidis (D24953, D24359) Malawi isolates were obtained from the Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi. D23580 is a representative invasive Malawian isolate belonging to ST313 sequence type isolated from a bacteraemic child [43, 44]. The clinical S. Typhimurium (Ke237, Ke238, Ke244, Ke249) and S. Enteritidis (Ke151, Ke180, Ke016, Ke117) Kenyan isolates were obtained from the Kenyan Medical Research Institute (KEMRI) in Nairobi, Kenya [37]. S. Typhimurium SL1344 and S. Enteritidis CMCC4314 are laboratory isolates [29, 45].

S. Agona 20071186 and S. Senftenberg 20050439 were obtained from Imperial College London; SL7488 from the University of Cambridge and S. Paratyphi A NVGH308 is a clinical isolate obtained from the Oxford University Clinical Research Unit-Nepal (OCRU-Nepal). Isolates were grown in Chemically Defined medium (CD medium) [11, 29, 46]. Glycerol was used as the carbon source with additional casamino acid supplementation (10g/L, BD Biosciences) depending upon the strain.

Strain Screening and Selection

**OAg extraction and quantification.** Bacteria were grown overnight in 100 mL liquid cultures. Liquid cultures were centrifuged in order to isolate the pellet. Bacterial pellets were washed with PBS and resuspended in water 2% acetic acid (pH 4) at OD 35, before performing acid hydrolysis at 100°C for 3 h. After hydrolysis, supernatant containing OAg were collected by centrifugation, neutralized with 14% NH₄OH and desalted on a HiTrap desalting 5 mL column, prepacked with Sephadex G-25 Superfine (GE Healthcare). Total sugar content was quantified by phenol sulfuric assay [29, 47].

**HPLC-SEC analysis.** OAg molecular weight (MW) distribution was evaluated by HPLC-SEC as previously described [30, 48]. Samples were run, without pretreatment, on a TSK gel G3000 PWXL column (30 cm x 7.8 mm; particle size 7 μm; cod. 808021) with a TSK gel PWXL guard column (4.0 cm x 6.0 mm; particle size 12 μm; cod. 808033) (Tosoh Bioscience). The mobile phase was 0.1 M NaCl, 0.1 M NaH₂PO₄, 5% CH₃CN, pH 7.2, at the flow rate of 0.5 mL/min (isocratic method for 30 min). Void and bed volume calibration was performed with λ-DNA (λ-DNA MW Marker III 0.12–21.2 kb; Roche) and sodium azide (NaN₃; Merck), respectively. OAg peaks were detected by differential refractive index (dRI). OAg average MW was estimated on standard dextrans (Sigma) calibration curve.

**HR–MAS NMR spectroscopy.** OAg were characterized directly on the bacteria without performing sample purification as previously described [29]. This method allowed detection of characteristic OAg sugars and O-acetylation pattern.

**Flow cytometry.** Bacteria were grown overnight in CD medium, diluted to OD 0.17 and incubated in 1:200 diluted (PBS, 1% BSA) serum samples obtained from immunized mice [10, 11]. After washing with PBS, bacteria were incubated with secondary anti-mouse APC-labeled antibody (Invitrogen, 1:400 in PBS 1% BSA), fixed in 4% formaldehyde and read using a FACS CANTO (BD Biosciences) flow cytometer (10,000 events recorded). As a negative control, bacteria were incubated with secondary antibody only. Values were obtained by the geometric means of fluorescent signals of positive bacteria (excitation: 650 nm, emission: 668 nm).

Fermentation of Selected Strains, OAg Purification and Characterization

Bacteria were grown in a 7-L bioreactor (EZ-Control; Applikon) to OD of approximately 35 as previously described [11, 46]. Growth conditions were controlled, keeping the temperature at
37 ± 0.5°C, pH at 6.7 (by addition of NH₄OH 28%), and pO₂ saturation at 30% (by agitation and pressure controls in cascade). All NTS strains were fermented in CD medium, except for \textit{S. Enteritidis} 618, which was grown in a complex medium containing: 10 g/L Soytone (BD Bioscience), 5g/L ultrafiltered yeast extract (Difco), 10 g/L NaCl, 3% glycerol. OAg purification was performed as previously described [29]. OAg purity was assessed by micro BCA for protein content, absorption at 260 nm for nucleic acid content and LAL for endotoxin level. MW distribution was evaluated by HPLC-SEC (dRI) and sugar composition by HPAEC-PAD. $^1$H-NMR was used for verifying sugar identity and measure O-acetylation level. KDO was quantified by HPLC-SEC/semicarbazide assay [29, 30].

**Synthesis and Characterization of Conjugate Vaccines**

Adipic acid dihydrazide (ADH) and then adipic acid bis(N-hydroxysuccinimmide) (SIDEA) linkers were introduced on the KDO sugar at the end of the core region with slight modifications at the methods previously described [32, 33]. For all \textit{S. Typhimurium} OAg-ADH-SIDEA, purification was performed precipitating the sugar by addition of dioxane (90% volume in the resulting solution), and then washing the pellet with the same organic solvent (ten times with 1/3 of the volume added for the precipitation) before lyophilization. For all \textit{S. Enteritidis} OAg-ADH-SIDEA, the reaction mixture was added to a volume (equal to two times the reaction mixture volume) of HCl 82.5 ppm and mixed at 4°C for 30 min. Under these conditions, unreacted SIDEA precipitated and was separated by centrifugation. OAg-ADH-SIDEA was recovered from the supernatant by precipitation with EtOH-HCl 55 ppm (85% volume in the final mixture). The pellet was washed four times with EtOH (2 volumes with respect to the reaction mixture volume) and lyophilized.

OAg-CRM$_{197}$ conjugates were synthesized as previously described [32, 33]. Conjugates were purified by hydrophobic interaction chromatography on a Phenyl HP column, loading 500 μg of protein for mL of resin in 50 mM NaH$_2$PO$_4$ 3M NaCl pH 7.2. The purified conjugate was eluted in water and the collected fractions were dialyzed against 10 mM NaH$_2$PO$_4$, pH 7.2.

The intermediates of conjugation were characterized as previously described [33]. Purified conjugates were characterized by phenol sulfuric acid assay [47] for total sugar content, micro BCA for total protein content and HPLC-SEC (TSK gel 6000-5000PW in series) for verifying conjugate formation in comparison to free protein and to estimate conjugate MW distribution [33].

**Immunogenicity Studies**

Two studies were conducted to compare the immunogenicity of \textit{S. Typhimurium} and \textit{S. Enteritidis} glycoconjugates. In both studies, five week-old female C57BL/6 mice (8 mice per group) from Charles River Laboratories were injected subcutaneously three times, at 2 week intervals, with 1 and 8 μg/dose of OAg (200 μL/dose). A control group of mice immunized with CRM$_{197}$ only at 8 μg/dose was included in the first study. Mouse sera were collected before the first immunization (day 0), on immunization days 14 and 28 and again two weeks after the third immunization, on day 42.

**Serum Antibody Analysis by ELISA**

Serum IgG levels against OAg were measured by ELISA [10, 28, 33]. Purified OAg from \textit{S. Typhimurium} D23580, SL1344, LT2, 1418, 2189, 2192 and \textit{S. Enteritidis} D24359, 502, 618, IV345219 were used for ELISA plate coating (5 μg/mL). Mouse sera were diluted 1:200 in PBS containing 0.05% Tween 20 and 0.1% BSA. ELISA units were expressed relative to mouse anti-OAg D23580 [10] or D24359 IgG standard serum curves, with best 4 parameter fit determined.
by modified Hill Plot. One ELISA unit was defined as the reciprocal of the standard serum dilution that gives an absorbance value equal to 1 in the assay. Each mouse serum was run in triplicate. Data are presented as scatter plots of individual mouse ELISA units, and geometric mean of each group.

**Adsorption experiments.** Pooled sera from each group of mice immunized with 8 μg/dose S. Typhimurium conjugates (day 42 sera) were pre-adsorbed with the following *Salmonella* serovars/strains to analyze IgG specificities: S. Agona 20071186 (expressing O:4 and O:12), S. Typhimurium D23580 (expressing O:1, O:4, O:5 and O:12), S. Typhimurium LT2 (expressing O:1, O:4, O:5 and O:12), S. Senftenberg 20050439 (expressing O:1, O:3 and O:19) [49], SL7488 (a mutant Thirsk isolate expressing O:4 instead of O:9, in addition to O:1 and 12) [50]. Bacteria were grown and normalized to OD 2 in 5 mL cultures. 750 μL of bacterial cultures were pelleted and washed with PBS and then resuspended in 250 μL of 1:200 diluted sera (in PBS–1% BSA) for overnight incubation at 4°C. Before performing the ELISA with mouse sera, bacteria with specific antibodies bound to their cell surface were removed by centrifugation.

To further dissect anti-OAg specificities, ELISA were also performed on pooled sera from each group of mice immunized with S. Typhimurium conjugates by coating plates with 5 μg/ml of purified OAg from: 1. S. Typhimurium D23580 (to test non pre-adsorbed sera, and sera after pre-adsorption with SL7488); 2. S. Paratyphi A (NVGH308, expressing O:1, O:2 and O:12); 3. S. Enteritidis D24359, expressing O:1, 9, 12 (to test non-pre-adsorbed sera, and sera after pre-adsorption with S. Senftenberg); 4. SL7488 (to test sera pre-adsorbed with S. Senftenberg); 5. S. Typhimurium LT2 (to test sera pre-adsorbed with SL7488) (Table 4).

**SBA**

Equal volumes of day 42 mouse serum, belonging to the same group of mice immunized with 8 μg/dose conjugates, were pooled for SBA experiments. S. Typhimurium and S. Enteritidis bacteria were grown in Luria Bertani (LB) medium to log-phase (OD: 0.2), diluted 1:15,000 in SBA buffer (50 mM phosphate; 0.041% MgCl2 6H2O; 33 mg/mL CaCl2; 0.5% BSA) and distributed into sterile polystyrene U bottom 96-well microtiter plates (15 μL/well). To each well (final volume 150 μL, 500–1000 colony forming units (CFU)/mL depending on the strain), serum samples serially diluted 5-fold (starting from 1:100 in well dilution) were added. Sera were heated at 56°C for 30 min to inactivate endogenous complement. Active Baby Rabbit Complement (BRC, Cederlane CL3441 lot6288) used at 50% of the final volume was added to each well. BRC source, lot and percentage used in the SBA reaction mixture were previously selected for low toxicity against S. Typhimurium and S. Enteritidis strains. To evaluate possible nonspecific inhibitory effects of BRC or mouse serum, bacteria were also incubated with the same tested sera plus heat-inactivated BRC; sera alone (no BRC); SBA buffer and active BRC. Each sample and control was tested in triplicate. One hundred microliter reaction mixture from each well was spotted on LB-agar plates at time zero (T0) to assess initial CFU, and at 3h (T180) after incubation at 37°C. LB-agar plates were incubated overnight at 37°C and resulting CFU were counted the following day. Bactericidal activity was determined as serum dilutions necessary to obtain 50% percent CFU reduction at T180 compared with T0. Serum titers equal to 1 were given when no bactericidal activity was detected.

**Statistical Analysis**

Statistical analysis of ELISA results was conducted on day 42 samples (mice receiving 8 μg/dose). Groups were compared using Kruskal-Wallis One-Way ANOVA. Post hoc analysis was performed using Student-Newman-Keuls test (using α = 0.05).
Ethical Statement

The mouse immunization experiments performed at the Novartis Animal Facility in Siena, Italy, complied with the relevant guidelines of Italy (Italian Legislative Decree n. 116/1992) and the institutional policies of Novartis. The animal protocol was approved by the Animal Welfare Body of Novartis Vaccines, Siena, Italy, and by the Italian Ministry of Health (Approval number AEC201018).

Supporting Information

S1 Fig. Representative fermentations of the selected nontyphoidal Salmonella strains. (A) S. Typhimurium, (B) S. Enteritidis. Td: duplication time.

S1 Table. SBA values obtained testing pooled sera from mice immunized with S. Typhimurium conjugates. Bactericidal activity was determined as serum dilutions necessary to obtain 50% percent CFU reduction at T180 compared with T0. Serum titers equal to 1 were given when no bactericidal activity was detected.

S2 Table. FACS values obtained testing pooled sera from mice immunized with S. Typhimurium conjugates.

S3 Table. SBA values obtained testing pooled sera from mice immunized with S. Enteritidis conjugates. Bactericidal activity was determined as serum dilutions necessary to obtain 50% percent CFU reduction at T180 compared with T0. Serum titers equal to 1 were given when no bactericidal activity was detected.

S4 Table. FACS values obtained testing pooled sera from mice immunized with S. Enteritidis conjugates.

Acknowledgments

The authors would like to acknowledge Vittoria Pinto and Francesco Berti for recording HR-MAS NMR spectra; BioQuotient /CEESA and University of Calgary for providing Salmonella strains and Breda Rogulj and Mae Shieh for managing the contractual aspects to obtain them. We also thank Robert Heyderman, Robert Onsare and Samuel Kariuki for providing the clinical Salmonella isolates.

Author Contributions

Conceived and designed the experiments: GS LL FM SR AS CM. Performed the experiments: LL GS FM SR. Analyzed the data: GS LL FM SR CM AS. Contributed reagents/materials/analysis tools: LL GS FM SR. Wrote the paper: FM SR GS LL AS CM.

References

1. Hendriksen RS, Vieira AR, Karlsmose S, Lo Fo Wong DM, Jensen AB, Wegener HC, et al. Global monitoring of Salmonella serovar distribution from the World Health Organization Global Foodborne Infections Network Country Data Bank: results of quality assured laboratories from 2001 to 2007. Foodborne Pathog Dis. 2011; 8: 887–900. doi: 10.1089/fpd.2010.0787 PMID: 21492021

2. Hohmann EL. Nontyphoidal salmonellosis. Clin Infect Dis. 2001; 32: 263–269. PMID: 11170916
3. Ao TT, Feasey NA, Gordon MA, Keddy KH, Angulo FJ, Crump JA. Global burden of invasive nontyphoidal Salmonella disease, 2010(1). Emerging infectious diseases. 2015; 21: 941–949.

4. Feasey NA, Dougan G, Kingsley RA, Heyderman RS, Gordon MA. Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa. Lancet. 2012; 379: 2489–2499. doi: 10.1016/S0140-6736(11)61752-2 PMID: 22587967

5. MacLennan CA, Levine MM. Invasive nontyphoidal Salmonella disease in Africa: current status. Expert Rev Anti Infect Ther. 2013; 11: 443–446. doi: 10.1586/eri.13.27 PMID: 23627848

6. MacLennan CA, Martin LB, Micoli F. Vaccines against invasive Salmonella disease: Current status and future directions. Hum Vaccin Immunother. 2014; 10: 1478–1493. doi: 10.4161/hv.29054 PMID: 24804797

7. Simon R, Levine MM. Glycoconjugate vaccine strategies for protection against invasive Salmonella infections. Hum Vaccin Immunother. 2012; 8: 494–498. doi: 10.4161/hv.19158 PMID: 22370510

8. Nagy G, Pal T. Lipopolysaccharide: a tool and target in enterobacterial vaccine development. Biol Chem. 2008; 389: 513–520. PMID: 18953717

9. Colwell DE, Michalek SM, Briles DE, Jirillo E, McGhee JR. Monoclonal antibodies to Salmonella lipopolysaccharide: anti-O-polysaccharide antibodies protect C3H mice against challenge with virulent Salmonella typhimurium. J Immunol. 1984; 133: 950–957. PMID: 6203984

10. Rondini S, Lanzilao L, Necchi F, O’Shaughnessy CM, Micoli F, Saul A, et al. Invasive African Salmonella Typhimurium induces bactericidal antibodies against O-antigens. Microb Pathog. 2013; 63: 19–23. doi: 10.1016/j.micpath.2013.05.014 PMID: 23756206

11. Rondini S, Micoli F, Lanzilao L, Gavini M, Alfìni R, Brandt C, et al. Design of glycoconjugate vaccines against invasive African Salmonella enterica serovar Typhimurium. Infect Immun. 2015; 83: 996–1007. doi: 10.1128/IAI.00379-14 PMID: 25547792

12. Simon R, Tennant SM, Wang JY, Lees A, Ernst RK, et al. Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H.g.m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis. Infect Immun. 2011; 79: 4240–4249. doi: 10.1128/IAI.05484-11 PMID: 21807909

13. Watson DC, Robbins JB, Szu SC. Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect Immun. 1992; 60: 4679–4686. PMID: 1383154

14. Svenson SB, Nurminen M, Lindberg AA. Artificial Salmonella vaccines: O-antigenic oligosaccharide-protein conjugates induce protection against infection with Salmonella typhimurium. Infect Immun. 1979; 25: 863–872. PMID: 387597

15. Konadu EY, Lin FY, Ho VA, Thuy NT, Van BP, Thanh TC, et al. Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun. 2000; 68: 1529–1534. PMID: 10678970

16. Svenson SB, Lindberg AA. Artificial Salmonella vaccines: Salmonella typhimurium O-antigen-specific oligosaccharide-protein conjugates elicit protective antibodies in rabbits and mice. Infect Immun. 1981; 32: 490–496. PMID: 616555

17. Murray GL, Attridge SR, Morona R. Inducible serum resistance in Salmonella typhimurium is dependent on wzz(fepE)-regulated very long O antigen chains. Microbes Infect. 2005; 7: 1296–1304. PMID: 16027021

18. Bravo D, Silva C, Carter JA, Hoare A, Alvarez SA, Blondel CJ, et al. Growth-phase regulation of lipopolysaccharide O-antigen chain length influences serum resistance in serovars of Salmonella. J Med Microbiol. 2008; 57: 938–946. doi: 10.1099/jmm.0.47848-0 PMID: 18628492

19. Westen MM, Kox LF, Chammongkol S, Soncini FC, Groisman EA. A signal transduction system that responds to extracellular iron. Cell. 2000; 103: 113–125. PMID: 11051552

20. Kato A, Grosman EA. Connecting two-component regulatory systems by a protein that protects a response regulator from dephosphorylation by its cognate sensor. Genes Dev. 2004; 18: 2302–2313. PMID: 15371344

21. Joiner KA, Grossman N, Schmetz M, Leive L. C3 binds preferentially to long-chain lipopolysaccharide during alternative pathway activation by Salmonella montevideo. J Immunol. 1986; 136: 710–715. PMID: 2416822

22. Morona R, van den Bosch L, Manning PA. Molecular, genetic, and topological characterization of O-antigen chain length regulation in Shigella flexneri. J. Bacteriol. 1995; 177: 1059–1068. PMID: 7532168

23. Murray GL, Attridge SR, Morona R. Regulation of Salmonella typhimurium lipopolysaccharide O antigen chain length is required for virulence; identification of FepE as a second Wzz. Mol Microbiol. 2003; 47: 1395–1406. PMID: 12603743
24. Helander IM, Moran AP, Makela PH. Separation of two lipopolysaccharide populations with different contents of O-antigen factor 122 in Salmonella enterica serovar typhimurium. Mol Microbiol. 1992; 6: 2857–2862. PMID: 1279361

25. Wollin R, Stocker BA, Lindberg AA. Lysogenic conversion of Salmonella typhimurium bacteriophages A3 and A4 consists of O-acetylation of rhamnose of the repeating unit of the O-antigenic polysaccharide chain. J Bacteriol. 1987; 169: 1003–1009. PMID: 3546260

26. Hellerqvist CG, Lindberg B., Svensson S., Holme T., Lindberg A.A.. Structural studies on the O-specific side chains of the cell-wall lipopolysaccharide from Salmonella typhimurium LT2. Carbohydr Res. 1969; 9: 237–241.

27. Slauch JM, Mahan MJ, Michetti P, Neutra MR, Mekalanos JJ. Acetylation (O-factor 5) affects the structural and immunological properties of Salmonella typhimurium lipopolysaccharide O antigen. Infect Immun. 1995; 63: 437–441. PMID: 7529745

28. Rondini S, Micoli F, Lanzilao L, Hale C, Saul AJ, Martin LB. Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi. Clin Vaccine Immunol. 2011; 18: 460–468. doi: 10.1128/CVI.00387-10 PMID: 21248155

29. Micoli F, Rondini S, Gavini M, Pisoni I, Lanzilao L, Colucci AM, et al. A scalable method for O-antigen purification applied to various Salmonella serovars. Anal Biochem. 2013; 434: 136–145. doi: 10.1016/j.ab.2012.10.038 PMID: 23142430

30. Micoli F, Ravenscroft N, Cescutti P, Stefanetti G, Londero S, Rondini S, et al. Structural analysis of O-polysaccharide chains extracted from different Salmonella Typhimurium strains. Carbohydr Res. 2014; 385: 1–8. doi: 10.1016/j.carres.2013.12.003 PMID: 24384528

31. Konadu E, Shilohajch, Bryla DA, Robbins JB, Szu SC. Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyl. Infect Immun. 1996; 64: 2709–2715. PMID: 6984949

32. Stefanetti G, Rondini S, Lanzilao L, Saul A, MacLennan CA, Micoli F. Impact of conjugation chemistry on the immunogenicity of S. Typhimurium conjugate vaccines. Vaccine. 2014; 32: 6122–6129. doi: 10.1016/j.vaccine.2014.08.056 PMID: 25192974

33. Micoli F, Rondini S, Gavini M, Lanzilao L, Medaglini D, Saul A, et al. O:2-CRM(197) conjugates against Salmonella Paratyphi A. PLoS One. 2012; 7: e47039. doi: 10.1371/journal.pone.0047039 PMID: 23144798

34. Jang H, Yoon YK, Kim JA, Kim HS, An SJ, Seo JH, et al. Optimization of Vi capsular polysaccharide production during growth of Salmonella enterica serotype Typhi Ty2 in a bioreactor. J Biotechnol. 2008; 135: 71–77. doi: 10.1016/j.jbiotec.2008.02.017 PMID: 18400326

35. Parker CT, Liebana E, Henzler DJ, Guard-Petter J. Lipopolysaccharide O-chain microheterogeneity of Salmonella serotypes Enteritidis and Typhimurium. Environ Microbiol. 2001; 3: 332–342. PMID: 11422930

36. Guard-Petter J, Parker CT, Asokan K, Carlson RW. Clinical and veterinary isolates of Salmonella enterica serovar enteritidis defective in lipopolysaccharide O-chain polymerization. Appl Environ Microbiol. 1999; 65: 2195–2201. PMID: 10224019

37. Onsare RS, Micoli F, Lanzilao L, Altini R, Okoro CK, Muigai AW, et al. Relationship between antibody susceptibility and lipopolysaccharide O-antigen characteristics of invasive and gastrointestinal nontyphoidal Salmonellae isolates from Kenya. PLoS Negl Trop Dis. 2015; 9: e0003573. doi: 10.1371/journal.pntd.2015.03573. PMID: 25739091

38. Ravenscroft N, Cescutti P, Gavini M, Stefanetti G, MacLennan CA, Martin LB, et al. Structural analysis of the O-acetylated O-polysaccharide isolated from Salmonella paratyphi A and used for vaccine preparation. Carbohydr Res. 2015; 404: 108–116. doi: 10.1016/j.carres.2014.12.002 PMID: 25665787

39. Liang-Takasaki CJ, Saxen H, Makela PH, Leive L. Complement activation by polysaccharide of lipopolysaccharide: an important virulence determinant of salmonellae. Infect Immun. 1983; 41: 565–569. PMID: 6347890

40. Beltran P, Plock SA, Smith NH, Whittam TS, Old DC, Selander RK. Reference collection of strains of the Salmonella typhimurium complex from natural populations. J Gen Microbiol. 1991; 137: 601–606. PMID: 2033380

41. Lilleeegen K. Typing Salmonella typhimurium by means of bacteriophage. Acta Pathol Microbiol Scand Supp. 1948; 77: 11–125.

42. de Jong A, Thomas V, Klein U, Marion H, Moyaert H, Simjee S, et al. Pan-European resistance monitoring programmes encompassing food-borne bacteria and target pathogens of food-producing and companion animals. Int J Antimicrob Agents. 2013; 41: 403–409. doi: 10.1016/j.ijantimicag.2012.11.004 PMID: 23394810
43. Kingsley RA, Msefula CL, Thomson NR, Kariuki S, Holt KE, Gordon MA, et al. Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype. Genome Res. 2009; 19: 2279–2287. doi:10.1101/gr.091017.109 PMID: 19901036

44. Okoro CK, Kingsley RA, Connor TR, Harris SR, Parry CM, Al-Mashhadani MN, et al. Intracontinental spread of human invasive Salmonella Typhimurium pathovariants in sub-Saharan Africa. Nat Genet. 2012; 44: 1215–1221. doi:10.1038/ng.2423 PMID: 23023330

45. Hoiseth SK, Stocker BA. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature. 1981; 291: 238–239. PMID: 7015147

46. Rondini S, Micoli F, Lanzilao L, Pisoni I, Di Cioccio V, Saul AJ, et al. Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM(197) glycoconjugate vaccine against Salmonella Typhi. J Infect Dev Ctries. 2012; 6: 763–773.

47. Dubois M, Giles KA, Hamilton JK, Rebers PA, Smith F. Colorimetric Method for Determination of Sugars and Related Substances. Anal Chem. 1956; 28: 350–356.

48. Micoli F, Romano MR, Tontini M, Cappelletti E, Gavini M, Proietti D, et al. Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. Proc Natl Acad Sci USA. 2013; 110: 19077–19082. doi: 10.1073/pnas.1314476110 PMID: 24191022

49. Berger CN, Brown DJ, Shaw RK, Minuzzi F, Feys B, Frankel G. Salmonella enterica strains belonging to O serogroup 1,3,19 induce chlorosis and wilting of Arabidopsis thaliana leaves. Environ Microbiol. 2011; 13: 1299–1308. doi: 10.1111/j.1462-2920.2011.02429.x PMID: 21349136

50. Hormaeche CE, Mastroeni P, Harrison JA, Demarco de Hormaeche R, Svenson S, Stocker BA. Protection against oral challenge three months after i.v. immunization of BALB/c mice with live Aro Salmonella typhimurium and Salmonella enteritidis vaccines is serotype (species)-dependent and only partially determined by the main LPS O antigen. Vaccine. 1996; 14: 251–259. PMID: 8744548